Severity of eczema at patch site during epicutaneous immunotherapy may predict subsequent response to oral immunotherapy

Camille Braun, Sharmili Sathasivam,Kathryn Samaan,François Graham,Louis Paradis,Anne Des Roches,Philippe Bégin

The Journal of Allergy and Clinical Immunology: In Practice（2023）

引用 0|浏览3

暂无评分

摘要

CLINICAL IMPLICATIONS BOX:Severity of eczema at patch application site during epicutaneous immunotherapy could be an independent predictor of subsequent response to oral immunotherapy. The delay between epicutaneous immunotherapy discontinuation and initiation of oral immunotherapy does not appear to affect response to the latter.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要